Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.40 |
| ▸ | GCGR | P47871 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194594 | 0.88 | MAPK14 (0.36) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5184567 | 0.87 | NPSR1 (0.39) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5199032 | 0.86 | GCGR (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5197480 | 0.86 | MAPK14 (0.38) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5199808 | 0.84 | OPRL1 (0.38) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5184636 | 0.83 | CNR1 (0.42) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5199024 | 0.82 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5199376 | 0.79 | CYP19A1 (0.45) | MAPK14MAPK13MAPK12MAPK11CYP19A1 | |
| SCHEMBL5184902 | 0.79 | CYP19A1 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5197184 | 0.78 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | claimed |
| US-20060173048-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-03 | — | — | US | claimed |
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173048-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173048-A1 | Imidazole derivatives | GRM2, GRM1, GRIN2C | MAPK14 2620/4885MAPK13 2722/4885MAPK12 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.